Summary

Other Scenarios:

Buyer: Cambrex Corporation (CBM) Last Price: 20.15 Market Cap.: 540.84M
Target: DepoMed, Inc. (DEPO) Last Price: 5.07 Market Cap.: 209.73M

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 868
Biopharmaceuticals   320
Outsourced Services 68
Scientific Products   43

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 38)
  • Generic Pharmaceutical Manufacturing Services
  • BioAssay Services
Target (Total: 7)
  • Gastric Retention System
Buyer
  • Cambrex Bioproducts
  • ApoGlow
  • Cell Analysis Reagents
  • Poietics- Human Differentiating Cell Systems
Target
  • Furosemide GR
  • Glumetza (Metformin GR)
  • Metformin/Sulfonylurea GR
  • Proquin XR (Ciprofloxacin Extended-Release)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 1)
  • Geron Corporation (GERN)
Target (Total: 1)
  • Biovail Corporation (USA) (BVF)
Buyer (Total: 10)
  • Alpharma Inc. (ALO)
  • Geron Corporation (GERN)
  • Aastrom Biosciences, Inc. (ASTM)
  • Tercica, Inc. (TRCA)
Target (Total: 5)
  • Esprit Pharma Holding Company, Inc.
  • Biovail Corporation (USA) (BVF)
  • King Pharmaceuticals (KG)
  • LG Group

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,041 90
Revenue Per Employee 235,523.7 59,808.3
Total Revenue 119.8 1.3
Total Expenses 109.0 9.7
Other Revenue 1.1 0.0
Cost of Revenue 74.9 0.1
SG&A Expense 28.2 3.9
Research & Development 6.0 5.7
Other Operating Expense 0.0 0.0
Operating Income 10.7 -8.3
Unusual Income 0.0 0.0
LT Debt to Capital 40.45 0
Fwd P/E 25.80 -8.56
Fwd P/Rev 1.13 14.77
Book Value 247.5 -10.8
Curr Portion of LTD/Cap Lease 0.0 0.0

Key Ratios

  Buyer Target
Gross Margin % 35.45 82.84
Operating Margin % -20.64 -472.79
Quick Ratio 1.31 5.83
Current Ratio 2.53 6.02
Coverage Ratio 0.12 0.01
Total Assets 596.8 61.5
Return on Equity % -57.33 -2,058.66
Return on Assets % -21.65 -41.34
Cash+ ST Inv. Per Share 1.72 1.34
Total Debt 188.3 0.0
Total Debt to Equity % 83.56 0
Total Debt to Tangible Equity % 210.45 0
Debt to Asset % 31.56 0.00

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Outsourced Services > Development/Manufacturing Services > Contract Manufacturing Organizations (CMO) > Pharmaceuticals > Active/Intermediate Chemicals

Target

Focused (): *Healthcare > Outsourced Services > Drug Delivery Technology > Oral Delivery > Polymer Coated

Business Description

Buyer

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services worldwide to pharmaceutical and biopharmaceutical companies, generic drug companies, biotechnology companies and research organizations. The Company is dedicated to providing essential products and services to accelerate drug discovery, development and manufacturing processes for human therapeutics. The Company operates in three segments: Bioproducts, Biopharma and Human Health.

Target

Depomed, Inc. is a specialty pharmaceutical company engaged in the development of pharmaceutical products, based on its oral drug delivery technologies. During the year ended December 31, 2005, the United States Food and Drug Administration (FDA) approved two products developed by the Company, ProQuin XR, a once-daily formulation of the antibiotic drug ciprofloxacin for uncomplicated urinary tract infections, and Glumetza, a once-daily metformin product for Type II diabetes. Depomed has also developed Gabapentin GR, an extended release form of gabapentin. In addition, the Company is applying its AcuForm technology to other compounds in an effort to enhance the safety, efficacy and/or dosing compliance of the innovator product.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Outsourced Services
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
  
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
  
Scientific Products  
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
  
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals  
Cardiovascular System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Furosemide GR
  
Endocrinology/Metabolism  
Diabetes  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.

Target Products:

  • Glumetza (Metformin GR)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Target Products:

  • Metformin/Sulfonylurea GR
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Narrow Spectrum  
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Target Products:

  • Proquin XR (Ciprofloxacin Extended-Release)
  
Neurology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Gabapentin GR
  
Oncology  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Target Products:

  • NeuGene Antisense Compound
  
Pain Management  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • Gabapentin GR
  
Outsourced Services
Development/Manufacturing Services  
Contract Manufacturing Organizations (CMO)  
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Buyer Products:

  • Generic Pharmaceutical Manufacturing Services
  
Drug Delivery Technology  
Oral Delivery  
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.

Target Products:

  • Gastric Retention System
  
Drug Discovery Services  
Lead Discovery/Validation/Optimization  
Assay Development
Bioanalytical services that are used to develop biologically based tests for use in high throughput screening (HTS).

Buyer Products:

  • BioAssay Services
  
Scientific Products  
Bioanalytical Instruments  
Biomolecular  
Electrophoresis  
Gel Electrophoresis (GE)  
Accessories
Supplementary products used to enhance the performance of a gel electrophoresis (GE) system.

Buyer Products:

  • Cambrex Bioproducts
  
Consumables  
Bioanalytical Chemistry  
Cell Biology  
Apoptosis  
Kits
A collection of reagents, standards, and other consumables assembled for used in apoptosis analyses.

Buyer Products:

  • ApoGlow
  
Reagents
Chemicals used in the preparation and analysis of samples during apoptosis analyses.

Buyer Products:

  • Cell Analysis Reagents
  
Cell Culture  
Cell Lines
Cell biology consumables that is a permanently established cell culture which proliferates indefinitely given appropriate fresh medium and space.

Buyer Products:

  • Poietics- Human Differentiating Cell Systems
  • Clonetics Primary Cell and Media Systems
  
Media
Cell biology consumables used for the growth of cells or organs.

Buyer Products:

  • Cambrex Bioproducts
  • Classical/Speciality Media
  
Reagents  
Antibiotics
Cell culture reagents that are used during cellular assays.

Buyer Products:

  • Cambrex Bioproducts
  
Growth Factors
Cell culture reagents that are used during cellular assays.

Buyer Products:

  • Cambrex Bioproducts
  
Stains/Dyes
Cell culture reagents used for the coloration of samples.

Buyer Products:

  • Cell Analysis Reagents
  
Sera  
Animal Sera
Sera obtained from animals.

Buyer Products:

  • Cambrex Bioproducts
  
Human Sera
Sera obtained from humans.

Buyer Products:

  • Cambrex Bioproducts
  
Cell Proliferation  
Kits
Cell proliferation consumables that are a collection of reagents, standards, and other consumables assembled for used in various biological analyses.

Buyer Products:

  • ViaLight Series
  
Cytotoxicity  
Kits
Consumables used in cytotoxicity analysis, which indicates destruction of target cells by measuring chemicals released by damaged cells.

Buyer Products:

  • ViaLight Series
  • Cell Analysis Reagents
  • ToxiLight
  
Signal Transduction  
Reagents
Chemicals used in the preparation and analysis of samples during signal transduction analyses.

Buyer Products:

  • G-Protein Coupled Receptors
  
Microbiology  
Identification/Detection  
Kits
A collection of reagents, standards, and other consumables assembled for used in various biological analyses.

Buyer Products:

  • MycoAlert Mycoplasma Detection Assay
  
Reagents
Microbial analysis reagents used for the detection of bateriocide endotoxins.

Buyer Products:

  • Cambrex Bioproducts
  
Stains/Dyes
Microbiological reagents used for the coloration of samples.

Buyer Products:

  • SYPRO
  • SYBR Green I
  • Cambrex Bioproducts
  
Molecular Biology  
Electrophoresis  
Gel Electrophoresis (GE)  
Gels
Gel electrophoresis consumable used for the separation of biological samples, including acrylamides, bisacrylamides, acrylamides/bisacrylamides, and agarose.

Buyer Products:

  • GelBond- Film
  • GelBond- PAG Film
  • ProSieve- Protein Markers
  • IsoGel- Agarose IEF Plates
  • Latitude- Precast
  • InCert
  • Duramide
  • FlashGel System
  • SeaPrep
  • SeaPlaque
  • SeaKem Series
  • Reliant
  • PAGEr Gold
  • NuSieve
  • MetaPhor
  • Long Ranger Singel
  • Latitude
  • IsoGel
  • I.D.NA
  
Reagents  
Buffers
Gel electrophoresis consumables that have a fixed concentration used to transfer the electrical current through.

Buyer Products:

  • AccuGENE
  
Stains/Dyes
Gel electrophoresis substances used for the coloration of samples.

Buyer Products:

  • SYBR Green I
  • SYPRO
  • GelStar
  
Standards
Gel electrophoresis chemicals used as a reference compound.

Buyer Products:

  • Megabase DNA
  
Microplate Readers  
Kits
Molecular biology consumable kits used with microplate readers

Buyer Products:

  • ReportaLight Plus
  
Nucleic Acid Analysis  
Kits  
Nucleic Acid  
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA

Buyer Products:

  • Cambrex Bioproducts
  
Protein Analysis  
Kits  
Detection
Protein analysis kits used for the detection of amino acids.

Buyer Products:

  • PKLight- HTS Protein Kinase Assay Kit
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Serologicals Corporation n/a 1,077.968 371.50 28.93 3.94 3.59 21.20
Target
  Johnson & Johnson n/a 179,023.626 16.69 16.38 3.53 3.38 6.34
Pfizer Inc. n/a 164,280.091 13.90 11.32 3.23 3.27 9.23
Bristol Myers Squibb Co. n/a 48,292.696 15.16 20.82 2.50 2.54 10.33
Bayer AG (ADR) n/a 33,354.713 17.12 14.98 0.94 1.04 6.05
Schering-Plough Corporation n/a 27,547.531 64.45 29.68 2.84 2.76 3.84
Teva Pharmaceutical Industries Ltd (ADR) n/a 22,963.450 n/a 15.89 4.09 2.74 -36.60
Barr Pharmaceuticals, Inc. n/a 4,789.275 15.96 14.76 3.85 3.79 4.26
Mylan Laboratories Inc. n/a 4,067.358 24.52 16.57 3.24 3.10 7.02
Biovail Corporation (USA) n/a 3,419.348 11.82 9.37 3.48 3.36 12.10
KOS Pharmaceuticals, Inc. n/a 1,817.123 21.26 23.67 2.36 2.14 3.80
Alpharma Inc. n/a 1,179.616 8.74 15.81 2.13 1.82 1.74
SkyePharma PLC (ADR) n/a 425.123 n/a n/a 3.78 n/a -3.65
Flamel Technologies S.A. (ADR) n/a 417.091 n/a -24.70 20.26 8.70 5.06
XenoPort, Inc. n/a 345.019 n/a -5.95 106.24 50.02 6.61
IVAX Diagnostics, Inc. n/a 46.698 n/a n/a 2.45 n/a 2.16
Access Pharmaceuticals, Inc. n/a 3.672 n/a n/a n/a n/a -0.37
Ranbaxy Laboratories Ltd. n/a n/a n/a n/a n/a n/a n/a
INTEC PHARMA LTD. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Geron Corporation n/a 409.337 n/a n/a 61.24 52.07 2.20
Target
  Biovail Corporation (USA) n/a 3,419.348 11.82 9.37 3.48 3.36 12.10

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Alpharma Inc. n/a 1,179.616 8.74 15.81 2.13 1.82 1.74
Geron Corporation n/a 409.337 n/a n/a 61.24 52.07 2.20
Aastrom Biosciences, Inc. n/a 173.055 n/a n/a 275.35 n/a 7.73
Tercica, Inc. n/a 159.532 n/a -2.49 1,864.85 37.39 2.05
CEL-SCI Corporation n/a 68.634 n/a n/a 460.70 n/a 33.59
Praecis Pharmaceuticals n/a 27.176 n/a n/a 3.94 n/a 0.60
DOR BioPharma, Inc. n/a 18.311 n/a n/a 4.21 n/a -11.47
Ortec International Inc. n/a 15.238 n/a n/a n/a n/a -0.42
Innovative Biosensors, Inc. n/a n/a n/a n/a n/a n/a n/a
Cyclacel Pharmaceuticals, Inc. n/a n/a n/a -2.61 n/a n/a n/a
Target
  Esprit Pharma Holding Company, Inc. 46.00% n/a n/a n/a n/a n/a n/a
Biovail Corporation (USA) 2.00% 3,419.348 11.82 9.37 3.48 3.36 12.10
King Pharmaceuticals n/a 4,081.203 41.62 10.65 2.16 2.21 4.35
LG Group n/a n/a n/a n/a n/a n/a n/a
Madaus AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  The Dow Chemical Company n/a 35,496.755 8.10 7.96 0.76 0.74 2.86
Alpharma Inc. n/a 1,179.616 8.74 15.81 2.13 1.82 1.74
Crucell N.V. (ADR) n/a 844.974 n/a -24.53 17.68 5.27 4.93
Geron Corporation n/a 409.337 n/a n/a 61.24 52.07 2.20
StemCells, Inc. n/a 189.671 n/a n/a 878.33 n/a 6.72
Aastrom Biosciences, Inc. n/a 173.055 n/a n/a 275.35 n/a 7.73
Tercica, Inc. n/a 159.532 n/a -2.49 1,864.85 37.39 2.05
Immtech Pharmaceuticals, Inc. n/a 84.674 n/a n/a 23.69 n/a 5.43
GTC Biotherapeutics, Inc. n/a 83.501 n/a -3.55 16.59 9.28 4.10
CEL-SCI Corporation n/a 68.634 n/a n/a 460.70 n/a 33.59
Praecis Pharmaceuticals n/a 27.176 n/a n/a 3.94 n/a 0.60
DOR BioPharma, Inc. n/a 18.311 n/a n/a 4.21 n/a -11.47
Ortec International Inc. n/a 15.238 n/a n/a n/a n/a -0.42
GlycoGenesys, Inc. n/a 0.634 n/a n/a n/a n/a 1.20
Cytori Therapeutics, Inc. n/a n/a n/a n/a n/a n/a n/a
Chugai Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Bristol Myers Squibb Co. n/a 48,292.696 15.16 20.82 2.50 2.54 10.33
King Pharmaceuticals n/a 4,081.203 41.62 10.65 2.16 2.21 4.35
Biovail Corporation (USA) n/a 3,419.348 11.82 9.37 3.48 3.36 12.10
New River Pharmaceuticals, Inc. n/a 1,042.040 n/a -42.00 48.86 24.44 365.76
AVI BioPharma, Inc. n/a 172.554 n/a -67.60 35.92 n/a 3.21
Boehringer Ingelheim GmbH n/a n/a n/a n/a n/a n/a n/a
Esprit Pharma Holding Company, Inc. n/a n/a n/a n/a n/a n/a n/a
LG Group n/a n/a n/a n/a n/a n/a n/a
Madaus AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 448.5 5.7 454.3
Other Revenue 6.5 0.0 6.5
Total Revenue 455.1 5.7 460.8
Cost of Revenue 293.8 1.0 294.7
SG&A Expense 105.3 13.9 119.2
Depreciation & Amortization 2.3 0.0 2.3
Research & Development 22.3 19.0 41.4
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 125.3 -1.1 124.3
Total Expenses 549.0 32.8 581.8
Operating Income -93.9 -27.1 -121.0
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -10.8 -0.2 -11.0
Other, Net -0.0 1.9 1.8
Income Before Taxes -104.8 -25.4 -130.2
Income Taxes 24.4 0.0 24.4
Income After Taxes -129.2 -25.4 -154.7
Net Income - Excl. Xord. Items -129.2 -25.4 -154.7
Net Income - Incl. Xord. Items -129.2 -25.4 -154.7
Preferred Dividends 0.0 -0.8 -0.8
Income Avail. to Common -129.2 -26.3 -155.5
Share Items
Basic Avg. Shares Outstanding 26.7 40.8 67.5
Basic EPS - Excl. Xord. Items -4.84 -0.65 -2.29
Basic EPS - Incl. Xord. Items -4.84 -0.65 -2.29
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 26.7 40.8 67.5
F.D. EPS - Excl. Xord. Items -4.84 -0.65 -2.29
F.D. EPS - Incl. Xord. Items -4.84 -0.65 -2.29
Dividends Per Common Share 0.12 0.00 0.12
Balance Sheet
Assets
Cash and Equivalents 45.9 8.2 54.1
ST Investments 0.0 46.5 46.5
Accounts Receivable 74.4 1.7 76.2
Inventory 93.6 0.7 94.3
Prepayments and Advances 17.7 1.2 18.9
Other Current Assets 1.2 0.0 1.2
Current Assets 232.8 58.3 291.1
Accum D&A 0.0 0.0 0.0
PPE, Net 222.1 3.0 225.1
Goodwill & Intangibles 135.9 0.0 135.9
Other Assets 0.0 0.0 0.0
Other LT Assets 6.0 0.2 6.2
Total Assets 596.8 61.5 658.3
Liabilities
Accounts Payable 38.8 2.1 40.9
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 51.8 2.9 54.7
ST Debt 1.5 0.0 1.5
Other (Current) Liabilities 0.0 4.6 4.6
Current Liab. 92.1 9.7 101.8
LT Debt 186.8 0.0 186.8
Total LT Debt 186.8 0.0 186.8
Deferred Taxes 31.1 0.0 31.1
Other LT Liab. 61.3 50.6 111.9
Total Liabilities 371.4 60.3 431.7
Shareholders Equity
Preferred Stock 0.0 12.0 12.0
Common Stock 0.0 141.5 141.5
Additional Paid in Capital 0.0 0.0 0.0
Retained Earnings 0.0 -152.2 -152.2
Other Equity 225.4 -0.1 225.3
Total Equity 225.4 1.2 226.6
Total Liab. & Equity 596.8 61.5 658.3
Shares Outstanding 26.7 41.3 68.0
Cash Flow
Operating Cash Flow
CF Net Income n/a -25.4 -25.4
CF Depreciation n/a 1.2 1.2
CF Deferred Taxes n/a 0.0 0.0
Other Non-Cash Items n/a -0.0 -0.0
Change in Working Capital n/a 53.8 53.8
Total Cash From Operating Activities n/a 29.4 29.4
Investing Cash Flow (not calculated)
Capital Expenditures n/a -0.8 -0.8
Other Investing Cash Flows n/a -24.0 -24.0
Total Cash From Investing Activities n/a -24.9 -24.9
Financing Cash Flow (not calculated)
Dividends Paid n/a 0.0 0.0
Purchase Or Sale of Stock n/a 3.0 3.0
Purchase and Retirement of Debt n/a -9.7 -9.7
Other Financing Cash Flow n/a 0.0 0.0
Total Cash From Financing Activities n/a -6.7 -6.7
Exchange Rate Effects n/a 0.0 0.0
Net Change in Cash n/a -2.1 -2.1
Cash Interest Paid n/a 0.5 0.5